Characteristics of Female Breast Cancer in Japan: Annual Report of the National Clinical Database in 2018

Overview

Journal Breast Cancer

Specialty Oncology

Date 2022 Dec 22

PMID 36547868

Authors

Keiichiro Tada

Hiraku Kumamaru

Hiroaki Miyata

Sota Asaga

Kotaro Iijima

Etsuyo Ogo

Takayuki Kadoya

Makoto Kubo

Yasuyuki Kojima

Kenta Tanakura

Kenji Tamura

Masayuki Nagahashi

Naoki Niikura

Naoki Hayashi

Minoru Miyashita

Masayuki Yoshida

Shinji Ohno

Shigeru Imoto

Hiromitsu Jinno

Affiliations

Soon will be listed here.

Abstract

Information regarding patients who were treated for breast cancer in 2018 was extracted from the National Clinical Database (NCD), which is run by Japanese physicians. This database continues from 1975, created by the Japanese Breast Cancer Society (JBCS). A total of 95,620 breast cancer cases were registered. The demographics, clinical characteristics, pathology, surgical treatment, adjuvant chemotherapy, adjuvant endocrine therapy, and radiation therapy of Japanese breast cancer patients were summarized. We made comparisons with other reports to reveal the characteristics of our database. We also described some features in Japanese breast cancer that changed over time. The unique characteristics of breast cancer patients in Japan may provide guidance for future research and improvement in healthcare services.

Citing Articles

Breast cancer statistics for Japan in 2022: annual report of the national clinical database-breast cancer registry-clinical implications including chemosensitivity of breast cancer with low estrogen receptor expression.

Nagahashi M, Kumamaru H, Kinukawa N, Iwamoto T, Kawashima M, Kinoshita T Breast Cancer. 2025; 32(2):217-226.

PMID: 39910023 PMC: 11842403. DOI: 10.1007/s12282-025-01671-0.

CDK4/6 inhibitor plus endocrine therapy for advanced breast cancer: results from a web-based survey in Japan.

Nakayama T, Xu L, Muramatsu Y Future Oncol. 2024; 21(3):321-330.

PMID: 39707711 PMC: 11792832. DOI: 10.1080/14796694.2024.2441649.

Safety and pharmacokinetics of vepdegestrant in Japanese patients with ER+ advanced breast cancer: a phase 1 study.

Iwata H, Naito Y, Hattori M, Yoshimura A, Yonemori K, Aizawa M Int J Clin Oncol. 2024; 30(1):72-82.

PMID: 39565495 PMC: 11700046. DOI: 10.1007/s10147-024-02648-3.

Capivasertib and fulvestrant for patients with HR-positive/HER2-negative advanced breast cancer: analysis of the subgroup of patients from Japan in the phase 3 CAPItello-291 trial.

Tokunaga E, Iwata H, Itoh M, Taira T, Toyama T, Mizuno T Breast Cancer. 2024; 32(1):132-143.

PMID: 39379782 PMC: 11717841. DOI: 10.1007/s12282-024-01640-z.

Economic impact of screening on postdiagnosis work productivity in Japanese women with breast cancer: a life-table modeling approach.

Takatori-Shirakami Y, Saito M, Yokoyama K Breast Cancer. 2024; 32(1):101-108.

PMID: 39365500 DOI: 10.1007/s12282-024-01637-8.

References

Rookus M, van Leeuwen F . Oral contraceptives and risk of breast cancer in women aged 20-54 years. Netherlands Oral Contraceptives and Breast Cancer Study Group. Lancet. 1994; 344(8926):844-51. DOI: 10.1016/s0140-6736(94)92826-6. View

Adami H, Hansen J, Jung B, RIMSTEN A . Familiality in breast cancer: a case-control study in a Sweden population. Br J Cancer. 1980; 42(1):71-7. PMC: 2010483. DOI: 10.1038/bjc.1980.204. View

Wolff A, Hammond M, Hicks D, Dowsett M, McShane L, Allison K . Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013; 31(31):3997-4013. DOI: 10.1200/JCO.2013.50.9984. View

Jobsen J, van der Palen J, Ong F, Riemersma S, Struikmans H . Bilateral breast cancer, synchronous and metachronous; differences and outcome. Breast Cancer Res Treat. 2015; 153(2):277-83. DOI: 10.1007/s10549-015-3538-5. View

Knudson A . Two genetic hits (more or less) to cancer. Nat Rev Cancer. 2002; 1(2):157-62. DOI: 10.1038/35101031. View

LILIENFELD A, Johnson E . The age distribution in female breast and genital cancers. Cancer. 1955; 8(5):875-82. DOI: 10.1002/1097-0142(1955)8:5<875::aid-cncr2820080504>3.0.co;2-z. View

Paul C, Skegg D, SPEARS G . Oral contraceptives and risk of breast cancer. Int J Cancer. 1990; 46(3):366-73. DOI: 10.1002/ijc.2910460305. View

Sattin R, Rubin G, Webster L, Huezo C, Wingo P, Ory H . Family history and the risk of breast cancer. JAMA. 1985; 253(13):1908-13. View

Sakai T, Ozkurt E, Desantis S, Wong S, Rosenbaum L, Zheng H . National trends of synchronous bilateral breast cancer incidence in the United States. Breast Cancer Res Treat. 2019; 178(1):161-167. DOI: 10.1007/s10549-019-05363-0. View

10.

ROSEMAN D, Straus A, SHOREY W . A positive family history of breast cancer. Does it effect diminish with age?. Arch Intern Med. 1990; 150(1):191-4. View

11.

Kurebayashi J, Miyoshi Y, Ishikawa T, Saji S, Sugie T, Suzuki T . Clinicopathological characteristics of breast cancer and trends in the management of breast cancer patients in Japan: Based on the Breast Cancer Registry of the Japanese Breast Cancer Society between 2004 and 2011. Breast Cancer. 2015; 22(3):235-44. DOI: 10.1007/s12282-015-0599-6. View

12.

Kubo M, Kumamaru H, Isozumi U, Miyashita M, Nagahashi M, Kadoya T . Annual report of the Japanese Breast Cancer Society registry for 2016. Breast Cancer. 2020; 27(4):511-518. PMC: 7297705. DOI: 10.1007/s12282-020-01081-4. View

13.

Anderson W, Reiner A, Matsuno R, Pfeiffer R . Shifting breast cancer trends in the United States. J Clin Oncol. 2007; 25(25):3923-9. DOI: 10.1200/JCO.2007.11.6079. View

14.

Hartman M, Czene K, Reilly M, Adolfsson J, Bergh J, Adami H . Incidence and prognosis of synchronous and metachronous bilateral breast cancer. J Clin Oncol. 2007; 25(27):4210-6. DOI: 10.1200/JCO.2006.10.5056. View

15.

Mruthyunjayappa S, Zhang K, Zhang L, Eltoum I, Siegal G, Wei S . Synchronous and metachronous bilateral breast cancer: clinicopathologic characteristics and prognostic outcomes. Hum Pathol. 2019; 92:1-9. DOI: 10.1016/j.humpath.2019.07.008. View

16.

Allott E, Shan Y, Chen M, Sun X, Garcia-Recio S, Kirk E . Bimodal age distribution at diagnosis in breast cancer persists across molecular and genomic classifications. Breast Cancer Res Treat. 2019; 179(1):185-195. PMC: 6985047. DOI: 10.1007/s10549-019-05442-2. View

17.

Hayashi N, Kumamaru H, Isozumi U, Aogi K, Asaga S, Iijima K . Annual report of the Japanese Breast Cancer Registry for 2017. Breast Cancer. 2020; 27(5):803-809. DOI: 10.1007/s12282-020-01139-3. View

18.

. The benefits and harms of breast cancer screening: an independent review. Lancet. 2012; 380(9855):1778-86. DOI: 10.1016/S0140-6736(12)61611-0. View